Boom! Repurchase! Silver Team! Hong Kong Healthcare (01931)’s "Stable Coin Blueprints" Come True?
HK Finance APP has learned that on July 29th, Hong Kong Healthcare (01931) announced a news that triggered market waves: its wholly-owned subsidiary, Wisdom Medical Devices (Shanghai) Co., Ltd. (hereinafter referred to as "Wisdom"), successfully completed a long-term sustainable development revolving credit financing agreement with a total amount of tens of billions of yuan, led by the Shanghai branch of East Asia Bank (China) Co., Ltd., and jointly participated by international and regional financial institutions such as Korea Enterprise Bank, Changhua Bank, Sumitomo Mitsui Bank, Sumitomo Mitsui Trust Bank, Shengjing Bank, and Busan Bank.
The choice of bank was not accidental. Just two weeks before the announcement, Hong Kong Healthcare's stock price experienced a crazy surge. From July 14th to 21st, its stock price rose by 75%, reaching a historic peak of HKD 4.66. Although it later fluctuated, its value remained stable above HKD 60 billion, far exceeding the year-end level.
The market's bullish sentiment behind this is Hong Kong Healthcare's strategic "nuclear bomb" - on July 17th, the company announced its plan to build a global-first focused medical innovation and high-tech assets ecosystem, naming it "IVDNewCo Exchange", and launching a proprietary stable coin called IVDDollar (IVDD). A revolutionary online movement that has officially started.
One: Bank Team, Jointly Invested in ConfidenceIn an era of constant credit tightening, Wisdom's approval for tens of billions of yuan in revolving credit financing is particularly valuable. According to the announcement, this loan agreement was signed on July 10th, 2025, and adopts a revolving mode that allows repeated withdrawals during the loan period, providing Wisdom with flexible and sufficient medium- and long-term funds, which also creates positive conditions for Hong Kong Healthcare's future financing needs, further optimizing its capital structure, and grasping opportunities in the growth of the industry.
The bank's choice is essentially a bet on the fundamental development prospects of a company.
Looking back at its fundamentals: since listing in 2019, Hong Kong Healthcare has seen continuous revenue and profit growth, despite facing challenges such as increased labor costs and technical service fees in the first half of 2025 (forecasting that the mother company's net profit attributable to shareholders will be no less than HKD 330 million), which has not shaken the confidence of financial institutions.
The bank's trust is more focused on the future. In the past month, Hong Kong Healthcare has been actively involved in capital market activities: from announcing its dual listing in Hong Kong and the United States to revealing a revolutionary "Web3 + Innovation Medicine" strategy, each step has been precisely aligned with the global trend of integrating healthcare and financial technology.
Two: High-Value Repurchase, Management's Confident DeclarationWhat will a company do when its stock price reaches a new historic high? Hong Kong Healthcare's choice is unexpected - it repurchased its shares.
From July 23rd to 28th, the company conducted three consecutive share repurchases: on July 23rd, it repurchased 141,400 shares at an average price of HKD 3.16; on July 25th, it repurchased 1.41 million shares at an average price of HKD 3.59; and on July 28th, it repurchased 166,000 shares at an average price of HKD 3.67. The total cost was over HKD 61.3 million, with the average repurchase price approaching the historic high.
This is not just ordinary hedging. Prior to May 8th, the company had announced a plan to repurchase 50 million shares at an average price of HKD 2.15, but at that time, the stock price was still relatively low. However, the recent share repurchases took place after the stock price surged by 75%, with the transaction price nearly double the year-end level. The bold move conveys management's confidence in its strategic prospects.
This self-confidence has a solid foundation of strategy. On July 20th, Hong Kong Healthcare registered its wholly-owned subsidiary, IVD GROUP INC., in New York, USA, and quickly launched the process of submitting stable coin registration applications to the SEC and CFTC. Only three days later, the company began high-value share repurchases - a strategic layout that aligns with market confidence, accurately grasping the rhythm.
A genuine repurchase is more convincing than any road show. When management dares to invest in its own shares at the peak price, investors read into it as a seal of approval for the "Web3 + Innovation Medicine" strategy.
Three: Strategic Ambition, Healthcare Assets' Chain RevolutionWhat will Hong Kong Healthcare do next? The announcement on July 17th sketches out a revolutionary picture: building an ecosystem called "IVDNewCo Exchange", which integrates medical innovation and high-tech assets with blockchain technology.
The traditional pharmaceutical research and development model has fatal flaws: it takes 10 years to develop a new drug, with 80% of funds concentrated in the clinical stage, and ordinary investors are excluded. Hong Kong Healthcare's plan is to use RWA (Real-World Asset) tokenization technology to convert high-value medical IP into chain-based assets.
This ecosystem consists of three pillars: RWA tokenization platform, decentralized exchange, and stable coin IVDD. This revolution lies in the value distribution mechanism. In traditional models, a new drug's 90% value is captured by capital after listing; whereas through RWA tokenization, early-stage investors can share clinical trial success milestones with Hong Kong Healthcare.
Hong Kong Healthcare aims to build a "Nasdaq + Uniswap" in the healthcare RWA field, ensuring compliance and decentralized efficiency. The plan is very attractive, but whether it can be realized depends on market acceptance.
From the perspective of technology trends, RWA is entering an explosive period. As of June 2025, the global RWA asset scale has reached USD 245.5 billion. According to a joint forecast by Boston Consulting Group (BCG) and ADDX, this market will balloon to USD 161 trillion by 2030, accounting for 10% of global GDP. Healthcare assets as high-value IP naturally adapt to tokenization.
The stable coin market is also building up. The total value of global stable coins has reached USD 263.6 billion, connecting fiat currency and cryptocurrency assets. According to a report by the Hong Kong Monetary Authority, stable coins can simplify payment processes, achieve "payment settlement", and have the potential to become a new type of financial infrastructure.
The regulatory window is also opening: Hong Kong's "Stable Coin Regulation" will take effect on August 1st; the European Union's "Cryptocurrency Market Supervision Act" has completed legislation; and the United States' "Genius Act" has established a stable coin regulation framework.
The regulatory breakthrough clears obstacles for Hong Kong Healthcare. The company's Web3 ecosystem, if successful, will open up new financing channels for these "locked" healthcare assets, reducing investment barriers and enhancing liquidity, allowing once-closed pharmaceutical research and development to enter a new era of openness.